NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Norris SL, Carson S, Thakurta S, et al. Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet]. Portland (OR): Oregon Health & Science University; 2008 Aug.

Cover of Drug Class Review: Thiazolidinediones

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].

Show details

References

1.
Centers for Disease Control and Prevention. National Diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Centers for Disease Control and Prevention. Atlanta, GA: Department of Health and Human Services; 2008.
2.
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2006;29(Suppl 1):S43–S48. 3/1/06. [PubMed: 16373932]
3.
Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136(5):664–672. [PubMed: 10802501]
4.
American Diabetes Association. The Prevention or Delay of Type 2 Diabetes. Diabetes Care. 2003;26(Suppl 1) 1/19/06. [PubMed: 12502620]
5.
Irons BK, Mazzolini TA, Greene RS. Delaying the Onset of Type 2 Diabetes Mellitus in Patients with Prediabetes. Pharmacotherapy. 2004;24(3):362–371. [PubMed: 15040650]
6.
Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med. 2002;346(6) 1/19/06. [PMC free article: PMC1370926] [PubMed: 11832527]
7.
Tuomilehto J, Lindstrom J, Eriksson JW, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350. [PubMed: 11333990]
8.
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the Stop-NIDDM randomised trial. Lancet. 2002;359 [PubMed: 12086760]
9.
Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes. 2002;51(9):2796–2803. [PubMed: 12196473]
10.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428. [PubMed: 15836891]
11.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607. [PubMed: 3056758]
12.
NCEP. Executive Summary of the Third Report of the National Cholestrol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholestrol in Adults (Adult Treatment Panel III) JAMA. 2001;285(19) [PubMed: 11368702]
13.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–553. [PubMed: 9686693]
14.
Einhorn D. American College of Endocrinology position statement on the insulin resistance syndrome. Endrocrine Practice. 2003 May–June;9(3):236–252.
15.
Ford E, Giles W, Dietz W. Prevalence of the Metabolic Syndrome Among US Adults. JAMA. 2002;287(3) [PubMed: 11790215]
16.
Cook S, Weitzman M, Auinger P, Nguyen M, Dietz W. Prevalence of a Metabolic Syndrome Phenotype in Adolescents. Arch Pediatr Adolesc Med. 2003 August:157. [PubMed: 12912790]
17.
Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004 May:164. [PubMed: 15159263]
18.
Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004;109(3):433–438. [PubMed: 14744958]
19.
National Institutes of Health. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health; 2001. Third Report of the National Cholestrol Education Program. NIH publication 01–3670 [ http://www​.access.gpo​.gov/su_docs/locators​/net/net_archive/net121001.html. [PubMed: 11368702]
20.
Wagstaff AJ, Goa KL. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2002;62(12):1805–1837. [PubMed: 12149047]
21.
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004 Jan;27(1):256–263. [PubMed: 14693998]
22.
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004 Sep 9;351(11):1106–1118. [PubMed: 15356308]
23.
Actos (pioglitazone) prescribing information. Available at: http://www​.fda.gov/cder​/foi/label/2004/21073s023lbl.pdf.2004.
24.
Avandia (rosiglitazone maleate) prescribing information. Available at: http://www​.fda.gov/cder​/foi/label/2005/021071s015lbl​.pdf.2005.
25.
Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med. 2004;140(10):786–794. [PubMed: 15148065]
26.
Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O’Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003;88(11):5137–5144. [PubMed: 14602740]
27.
Jansen PLM. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16(11):1079–1085. 12/26/2007. [PubMed: 15489564]
28.
Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 Sep 18;147(6):386–399. [PubMed: 17638715]
29.
Harris RP, Helfand M, Woolf S. Current methods of the third US Preventative Services Task Force. Am J Prev Med. 2001;20(3S):21–35. [PubMed: 11306229]
30.
Anonymous. CRD Report Number 4 (2nd Edition). 2nd Ed. Vol. 4. York, UK: NHS Centre for Reviews and Dissemination; 2001. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews.
31.
Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (updated May 2005). 2005. 12/31/2007.
32.
DerSimonian R, Laird N. Meta-analyses in clinical trials. Control Clin Trials. 1954;7:177–188. [PubMed: 3802833]
33.
Glenny A, Altman D, Song F, et al. Indirect comparisons of competing interventions. Health Technology Assessment (Winchester, England) 2005;9( 26):1–134. [PubMed: 16014203]
34.
Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. 1/25/06. [PMC free article: PMC192859] [PubMed: 12958120]
35.
Henry RR. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther. 2003;25( Suppl B):B47–63. [PubMed: 14553866]
36.
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372. [PubMed: 11790216]
37.
Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004;26(2):177–190. [PubMed: 15038941]
38.
Noble J, Baerlocher MO, Silverberg J. Management of type 2 diabetes mellitus. Role of thiazolidinediones. Can Fam Physician. 2005;51:683–687. [PMC free article: PMC1472920] [PubMed: 15934272]
39.
Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther. 2003;25( Suppl B):B4–31. [PubMed: 14553864]
40.
van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23(10):1744–1749. [PubMed: 12907465]
41.
Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23(11):1792–1823. [PubMed: 11768834]
42.
Boucher M, McAuley L, Brown A, Keely E, Skidmore B. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Ottawa Canadian Coordinating Office for Health Technology Assessment. Technology overview no 9. 2002
43.
Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097–2104. [PubMed: 15505122]
44.
Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess. 2004;8(13):iii. [PubMed: 15038907]
45.
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract. 2007 May;76(2):279–289. [PubMed: 17055103]
46.
Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007 Sep 8;335(7618):497. [PMC free article: PMC1971204] [PubMed: 17761999]
47.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007 Sep 29;370(9593):1129–1136. [PubMed: 17905165]
48.
Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials. Curr Med Res Opin. 2006 Nov;22(11):2267–2278. [PubMed: 17076987]
49.
Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care. 2007 Feb;30(2):384–388. [PubMed: 17259517]
50.
Richter Bandeira E, Bergerhoff Clar, Ebrahim Sh. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2007;4:4. [PubMed: 17636824]
51.
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2006;(4):CD006060. [PubMed: 17054272]
52.
Rosmarakis ES, Falagas ME. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J. 2007 Jul;154(1):144–150. [PubMed: 17584567]
53.
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189–1195. [PubMed: 17848653]
54.
Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007 Aug;30(8):2148–2153. [PubMed: 17536074]
55.
Richter Bandeira E, Bergerhoff, Ebrahim Sh. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2007;4:4. [PubMed: 18425967]
56.
Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol. 2007;49(16):1696–1704. [PubMed: 17448371]
57.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England journal of medicine. 2006;355(23):2427–2443. [PubMed: 17145742]
58.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007 Jul 5;357(1):28–38. [PubMed: 17551159]
59.
Investigators DT, Bosch J, Yusuf S, et al. Effect of ramipril on the incidence of diabetes. The New England journal of medicine. 2006;355(15):1551–1562. [PubMed: 16980380]
60.
Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005 Oct 8;366(9493):1279–1289. [PubMed: 16214598]
61.
Centre for Reviews and D. Efficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents: systematic review and budget impact analysis (Structured abstract) Database of Abstracts of Reviews of Effectiveness. 2006;1:1.
62.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007 Sep 12;298(10):1180–1188. [PubMed: 17848652]
63.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457–2471. [PubMed: 17517853]
64.
Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28(3):736–744. [PubMed: 15735219]
65.
Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelvemonth, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004;26(5):744–754. 12/26/07. [PubMed: 15220018]
66.
Derosa G, Cicero AFG, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract. 2005;69(1):5–13. [PubMed: 15955382]
67.
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–1554. 12/26/2007. [PubMed: 15983299]
68.
Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25(4):708–711. [PubMed: 11919129]
69.
Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev. 2007 Jul;23(5):392–399. [PubMed: 17211855]
70.
Derosa G, Dangelo A, Ragonesi PD, et al. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. The Journal of international medical research. 2006;34(5):545–555. [PubMed: 17133785]
71.
Derosa G, Cicero AF, D’Angelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther. 2006;28(5):679–688. [PubMed: 16861090]
72.
Derosa G, D’Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006;31(4):375–383. [PubMed: 16882108]
73.
Derosa G, D’Angelo A, Ragonesi PD, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal medicine journal. 2007;37(2):79–86. [PubMed: 17229249]
74.
Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertension research : official journal of the Japanese Society of Hypertension. 2007;30(5):387–394. [PubMed: 17587750]
75.
Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertension research : official journal of the Japanese Society of Hypertension. 2005;28(11):917–924. [PubMed: 16555581]
76.
Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 2004;27(6):1324–1329. [PubMed: 15161783]
77.
Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517–523. [PubMed: 11874940]
78.
Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146(2):E5. [PubMed: 12891212]
79.
Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772–1780. [PubMed: 17466227]
80.
Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) Stroke; a journal of cerebral circulation. 2007;38(3):865–873. [PubMed: 17290029]
81.
Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605–1611. 12/26/2007. [PubMed: 11092281]
82.
Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine. 2006;355(22):2297–2307. [PubMed: 17135584]
83.
Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093–1104. [PubMed: 15889234]
84.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol. 2007 [PubMed: 17106061]
Endocrinology and metabolism. 292(3):E871–883. [PubMed: 17106061]
85.
Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 2003;25(4):1074–1095. [PubMed: 12809958]
86.
Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10–17. [PubMed: 11448655]
87.
Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005;27(5):554–567. [PubMed: 15978304]
88.
McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF. Effect of a peroxisome proliferator-activated receptor-(gamma) agonist on myocardial blood flow in type 2 diabetes. Diabetes Care. 2005;28(5):1145–1150. [PMC free article: PMC4231709] [PubMed: 15855580]
89.
Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24(4):710–719. [PubMed: 11315836]
90.
Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(9):4312–4319. [PubMed: 15356026]
91.
Gastaldelli A, Miyazaki Y, Mahankali A, et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care. 2006;29(10):2275–2281. [PubMed: 17003306]
92.
Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004;29(1):11–17. [PubMed: 15258553]
93.
Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care. 2006 Jan;29(1):101–106. [PubMed: 16373904]
94.
Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413–423. [PubMed: 11491207]
95.
Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56(4):251–257. [PubMed: 12074206]
96.
Scherbaum WA, Goke B. German Pioglitazone Study G. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res. 2002;34(10):589–595. [PubMed: 12439788]
97.
Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005;54(1):24–32. [PubMed: 15562376]
98.
Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care. 2004;27(7):1660–1667. [PubMed: 15220243]
99.
Tseng CH, Huang TS. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients. Diabetes Res Clin Pract. 2005;70(2):193–194. [PubMed: 16188579]
100.
Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med. 2004;21(6):568–576. [PubMed: 15154941]
101.
Honisett SY, Stojanovska L, Sudhir K, Kingwell BA, Dawood T, Komesaroff PA. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care. 2003;26(11):3194–3195. [PubMed: 14578270]
102.
Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000;43(3):278–284. [PubMed: 10768088]
103.
Wang G, Wei J, Guan Y, Jin N, Mao J, Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism. 2005;54(5):590–597. [PubMed: 15877288]
104.
Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med. 2000;17(4):287–294. [PubMed: 10821295]
105.
Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116(4):223–229. [PubMed: 14969649]
106.
Lautamaki R, Airaksinen KEJ, Seppanen M, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes. 2005 Sep;54(9):2787–2794. [PubMed: 16123370]
107.
Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract. 2005 Oct;70(1):20–25. [PubMed: 16126119]
108.
Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J. 2004;147(5):e23. [PubMed: 15131558]
109.
Pfutzner A, Hohberg C, Lubben G, et al. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Horm Metab Res. 2005 Aug;37(8):510–515. [PubMed: 16138265]
110.
Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006;8(1):49–57. [PubMed: 16367882]
111.
Pfutzner A, Schondorf T, Seidel D, et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism. 2006 Jan;55(1):20–25. [PubMed: 16324915]
112.
Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Version; 2003.
113.
Barnett AH, Grant PJ, Hitman GA, et al. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Diabet Med. 2003 May;20(5):387–393. [PubMed: 12752488]
114.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695–1702. [PubMed: 10755495]
115.
Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18(2):127–134. [PubMed: 11994904]
116.
Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51(12):3479–3485. [PubMed: 12453903]
117.
Iozzo P, Hallsten K, Oikonen V, et al. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Diabetes Care. 2003;26(7):2069–2074. [PubMed: 12832315]
118.
Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(3):163–170. [PubMed: 12681023]
119.
Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract. 2005;67(1):43–52. [PubMed: 15620433]
120.
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280–288. [PubMed: 11232013]
121.
Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia. 2001;44(12):2210–2219. [PubMed: 11793023]
122.
Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–1357. [PubMed: 15161787]
123.
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1(3):165–172. [PubMed: 11220295]
124.
Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315. [PubMed: 11213884]
125.
Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–1232. [PubMed: 11423507]
126.
Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4(4):270–275. [PubMed: 12099976]
127.
Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005;48(1):83–95. [PubMed: 15619071]
128.
van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care. 2005;28(4):844–849. [PubMed: 15793183]
129.
Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 2003;52(2):283–290. [PubMed: 12540598]
130.
Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med. 2000;17(1):40–47. [PubMed: 10691158]
131.
Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25(2):376–380. [PubMed: 11815513]
132.
Zhu XX, Pan CY, Li GW, et al. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther. 2003;5(1):33–42. [PubMed: 12725705]
133.
Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68(1):285–292. [PubMed: 15954919]
134.
Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29(3):510–514. [PubMed: 16505497]
135.
Heliovaara MK, Herz M, Teppo AM, Leinonen E, Ebeling P. Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. J Endocrinol Invest. 2007;30(4):292–297. [PubMed: 17556865]
136.
Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388–1395. [PubMed: 16999648]
137.
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA : the journal of the American Medical Association. 2006;296(21):2572–2581. [PubMed: 17101640]
138.
Perriello G, Pampanelli S, Di Pietro C, Brunetti P. Italian Pioglitazone Study G. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. 2006;23(3):246–252. [PubMed: 16492206]
139.
Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol. 2006;65(6):722–728. [PubMed: 17121522]
140.
Teramoto T, Yamada N, Shirai K, Saito Y. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. Journal of atherosclerosis and thrombosis. 2007;14(2):86–93. [PubMed: 17485893]
141.
Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22(4):751–759. [PubMed: 16684436]
142.
Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association. 2005;22(8):980–985. [PubMed: 16026361]
143.
Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047–2055. [PubMed: 16957566]
144.
Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab. 2006;8(2):197–205. [PubMed: 16448524]
145.
Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156–163. [PubMed: 16448519]
146.
Goldstein BJ, Weissman PN, Wooddell MJ, Waterhouse BR, Cobitz AR. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Curr Med Res Opin. 2006;22(9):1715–1723. [PubMed: 16968575]
147.
Hanefeld M, Patwardhan R, Jones NP. Rosiglitazone Clinical Trials Study G. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2007;17(1):13–23. [PubMed: 17174222]
148.
Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007 Jun;24(6):626–634. [PMC free article: PMC1974811] [PubMed: 17517066]
149.
Kulenovic I. Impact of rosiglitazone on glycaemic control, insulin levels and blood pressure values in patients with type 2 diabetes. Medicinski arhiv. 2006;60(3):179–181. [PubMed: 16719233]
150.
Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med. 2004;21(4):329–335. [PubMed: 15049934]
151.
Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153(3):445.e441–446. [PubMed: 17307426]
152.
Choi D, Kim S-K, Choi S-H, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004 Nov;27(11):2654–2660. [PubMed: 15505001]
153.
Davidson JA, Perez A, Zhang J. The Pioglitazone 343 Study G. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab. 2006;8(2):164–174. [PubMed: 16448520]
154.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. [PubMed: 18378631]
155.
Viberti G, Lachin J, Holman R, et al. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabetic medicine : a journal of the British Diabetic Association. 2006;23(12):1289–1294. [PubMed: 17116177]
156.
Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab. 2004;6(4):280–285. 12/28/2007. [PubMed: 15171752]
157.
Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Clin Pract. 2005;59(2):134–142. [PubMed: 15854187]
158.
Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93(3):362–365. [PubMed: 14759393]
159.
Hung YJ, Hsieh CH, Pei D, et al. Rosiglitazone improves insulin sensitivity and glucose tolerance in subjects with impaired glucose tolerance. Clin Endocrinol. 2005;62(1):85–91. [PubMed: 15638875]
160.
Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J. 2007;154(1):137–143. [PubMed: 17584566]
161.
DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47(9):1519–1527. [PubMed: 15322749]
162.
Rasouli N, Raue U, Miles LM, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005;288(5 51–5):E930–E934. [PubMed: 15632102]
163.
Bennett SM, Agrawal A, Elasha H, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004;21(5):415–422. [PubMed: 15089784]
164.
Kahn SR, Zinman B, Lachin J, et al. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care. 2008;31(5):845–851. [PubMed: 18223031]
165.
King KA, Levi VE. Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. Am J Health Syst Pharm. 2004;61(4):390–393. [PubMed: 15011768]
166.
Hussein Z, Wentworth JM, Nankervis AJ, Proietto J, Colman PG. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust. 2004;181(10):536–539. [PubMed: 15540964]
167.
Tang WH, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41(8):1394–1398. [PubMed: 12706937]
168.
GlaxoSmithKline. Dear Healthcare Provider. Available at: http://www​.fda.gov/medwatch​/safety/2006/Avandia_DHCPletter​.pdf.2005.
169.
Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26(11):2983–2989. [PubMed: 14578227]
170.
Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24(3):378–396. [PubMed: 11952022]
171.
LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin. 2002;18(6):363–370. [PubMed: 12442884]
172.
Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25( Suppl B):B64–80. [PubMed: 14553867]
173.
Gegick CG, Altheimer MD. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin. 2004;20(6):919–930. [PubMed: 15200751]
174.
Harmel AP. Treating diabetes: Cardiovascular benefits of antidiabetes drugs. Am J Manag Care. 2002;8(8 SUPPL):S219–228. [PubMed: 12022237]
175.
King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care. 2000;23(4):557. [PubMed: 10857952]
176.
Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006 Jun;22(6):1211–1215. [PubMed: 16846554]
177.
Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiology & Drug Safety. 2007 May;16(5):504–512. [PubMed: 17245800]
178.
Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care. 2007 Jul;30(7):1689–1693. [PubMed: 17440170]
179.
Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005 Aug;22(8):986–993. [PMC free article: PMC3557913] [PubMed: 16026362]
180.
Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiology & Drug Safety. 2007 May;16(5):485–492. [PubMed: 17192841]
181.
Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005 Feb 8;111(5):583–590. [PubMed: 15699279]
182.
McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiology & Drug Safety. 2007 Jul;16(7):711–725. [PubMed: 17551989]
183.
Hartung DM, Touchette DR, Bultemeier NC, Haxby DG. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy. 2005 Oct;25(10):1329–1336. [PubMed: 16185176]
184.
Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes Relat Metab Disord. 2004;28(6):783–789. [PubMed: 15024400]
185.
Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90(9):947–952. [PubMed: 12398960]
186.
Hayashi Y, Miyachi N, Takeuchi T, et al. Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile. Diabetes Obes Metab. 2003;5(1):58–65. [PubMed: 12542726]
187.
Jung W, Jung S. Effects of pioglitazone and insulin on tight glycaemic control assessed by the continuous glucose monitoring system: A monocentric, parallel-cohort study. Clin Drug Invest. 2005;25(5):347–352. [PubMed: 17532673]
188.
Kiayias JA, Vlachou ED, Theodosopoulou E, Lakka-Papadodima E. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care. 2002;25(7):1251–1252. [PubMed: 12087036]
189.
King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther. 2002;4(2):145–151. [PubMed: 12079617]
190.
King AB, Armstrong DU, Chinnapongse S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care. 2003;26(1):245–246. [PubMed: 12502690]
191.
Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J. 2002;49(3):323–328. [PubMed: 12201216]
192.
Marceille JR, Goins JA, Soni R, Biery JC, Lee TA. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy. 2004;24(10):1317–1322. [PubMed: 15628829]
193.
Miyazaki Y, De Filippis E, Bajaj M, et al. Predictors of improved glycaemic control with rosiglitazone therapy in type 2 diabetic patients: A practical approach for the primary care physician. Br J Diabetes Vas Dis. 2005;5(1):28–35.
194.
Ono M, Ikegami H, Fujisawa T, et al. Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones. Metabolism. 2005;54(4):529–532. [PubMed: 15798962]
195.
Orbay E, Sargin M, Sargin H, Gozu H, Bayramicli OU, Yayla A. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Endocr J. 2004;51(6):521–527. [PubMed: 15644569]
196.
Osei K, Gaillard T, Kaplow J, Bullock M, Schuster D. Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism. 2004;53(12):1552–1557. [PubMed: 15562399]
197.
Pietruck F, Kribben A, Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int. 2005;18(4):483–486. [PubMed: 15773972]
198.
Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther. 2004;26(9):1400–1410. [PubMed: 15531002]
199.
Roy R, Navar M, Palomeno G, Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population. Diabetes Care. 2004;27(7):1741–1742. [PubMed: 15220256]
200.
Sarafidis PA, Lasaridis AN, Nilsson PM, et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens. 2004;22(9):1769–1777. [PubMed: 15311106]
201.
Schofl C, Lubben G. Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice. Clin Drug Invest. 2003;23(11):725–734. [PubMed: 17536886]
202.
Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drug Aging. 2004;21(4):259–271. [PubMed: 15012171]
203.
Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol. 2005;100(6):1317–1321. 12/31/2007. [PubMed: 15929763]
204.
Bell DSH, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab. 2006 Jan;8(1):110–115. [PubMed: 16367889]
205.
Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clinical Pharmacology & Therapeutics. 2007 Sep;82(3):275–281. [PubMed: 17361126]
206.
Biesenbach G, Grafinger P, Raml A. Improvement of glycemic control after a 3–5 day insulin infusion in type 2-diabetic patients with insulin resistance can be maintained with glitazone therapy. Wiener klinische Wochenschrift. 2006;118(17–18):543–548. [PubMed: 17009067]
207.
Chiang CK, Ho TI, Peng YS, et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care. 2007;30(1):3–7. [PubMed: 17192324]
208.
Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol. 2006 Jul;65(1):35–39. [PubMed: 16817816]
209.
Dorkhan M, Magnusson M, Frid A, Grubb A, Groop L, Jovinge S. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med. 2006;260(2):125–133. [PubMed: 16882276]
210.
Kahara T, Takamura T, Misaki T, et al. Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. Endocr J. 2005 Jun;52(3):373–376. [PubMed: 16006733]
211.
Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y, Group PS. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract. 2007 May;76(2):229–235. [PubMed: 17109986]
212.
Kim S-K, Hur K-Y, Kim H-J, et al. The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. Eur J Endocrinol. 2007 Aug;157(2):167–174. [PubMed: 17656594]
213.
Lee J-K, Chu C-H, Chuang M-J, et al. Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients. Chang Gung Medical Journal. 2006 Sep–Oct;29(5):486–492. [PubMed: 17214393]
214.
Otto C, Otto B, Goke B, et al. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest. 2006 Mar;29(3):231–236. [PubMed: 16682836]
215.
Panikar V, Joshi SR, Bukkawar A, Nasikkar N, Santwana C. Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination. J Assoc Physicians India. 2007 May;55:333–337. [PubMed: 17844692]
216.
Rajagopalan R, Xu Y, Abbadessa M. Quartet Study G. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials. American Journal Geriatric Pharmacotherapy. 2006 Jun;4(2):123–133. [PubMed: 16860259]
217.
Rosak C, Petzoldt R, Wolf R, Reblin T, Dehmel B, Seidel D. Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. Int J Clin Pract. 2005 Oct;59(10):1131–1136. [PubMed: 16178978]
218.
Rosak C, Standl E, Reblin T, Stammer H, Seidel DK. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract. 2006 Sep;60(9):1040–1047. [PubMed: 16939544]
219.
Sauer WH, Cappola AR, Berlin JA, Kimmel SE. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol. 2006 Mar 1;97(5):651–654. [PubMed: 16490431]
220.
Schondorf T, Forst T, Hohberg C, et al. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab. 2007 Jan;9(1):132–133. [PubMed: 17199730]
221.
Shim WS, Do MY, Kim SK, et al. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol. 2006 Oct;65(4):453–459. [PubMed: 16984237]
222.
Tan M, Johns D, Gonzalez Galvez G, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004;26(5):680–693. [PubMed: 15220012]
223.
Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med. 2004;21(8):859–866. [PubMed: 15270789]
224.
St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–2064. [PubMed: 12401757]
225.
Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea. Acta Diabetol. 2004;41(2):63–69. [PubMed: 15224207]
226.
Vongthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin. 2002;18(8):456–461. [PubMed: 12564655]
227.
Kerenyi Z, Samer H, James R, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004;63(3):213–223. [PubMed: 14757293]
228.
Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27(7):1647–1653. [PubMed: 15220241]
229.
Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: Results from a controlled randomized study. Circulation. 2005;111(19):2525–2531. [PubMed: 15883215]
230.
Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925–1931. [PubMed: 15963388]
231.
Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167–174. [PubMed: 15386821]
232.
Watanabe A, Komine F, Nirei K, et al. A case of secondary diabetes mellitus with acromegaly improved by pioglitazone. Diabet Med. 2004;21(9):1049–1050. 12/31/2007. [PubMed: 15317614]
233.
Kreider M, Heise M. Rosiglitazone in the management of older patients with type 2 diabetes mellitus. Int J Clin Pract. 2002;56(7):538–541. [PubMed: 12296617]
234.
Jun JK, Gong WC, Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm. 2003;60(5):469–473. [PubMed: 12635453]
235.
Chan NN, Tong PC, So WY, Leung WY, Chiu CK, Chan JC. The metabolic effects of insulin and rosiglitazone combination therapy in Chinese type 2 diabetic patients with nephropathy. Med Sci Mon. 2004;10(3):PI44–48. [PubMed: 14976448]
236.
Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy. 2003;23(7):861–865. [PubMed: 12885099]
237.
Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care. 2006;29(5):1039–1045. [PubMed: 16644634]
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10743

Views

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...